Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.33 HKD | -1.48% | -4.32% | -8.90% |
04-03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
04-03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
ETFs positioned on Ascletis Pharma Inc.
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.78% | 4 M€ | -27.92% | ||
0.00% | 34 M€ | +4.77% | - |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.90% | 175M | |
-2.99% | 89.49B | |
+2.50% | 40.67B | |
-12.01% | 33.15B | |
+63.12% | 26.45B | |
-19.79% | 14.69B | |
-8.58% | 12.89B | |
-12.34% | 11.54B | |
-43.92% | 11.34B | |
+3.82% | 8.84B |
- Stock Market
- Equities
- 1672 Stock
- Funds and ETFs Ascletis Pharma Inc.